<DOC>
	<DOCNO>NCT01959425</DOCNO>
	<brief_summary>The objective study determine safety discontinue oral anticoagulation therapy high risk patient successful cardiac ablation remain AF recurrence free 3 month post ablation .</brief_summary>
	<brief_title>Oral Anticoagulation Therapy Pilot Study</brief_title>
	<detailed_description>Patients undergo successful cardiac ablation atrial fibrillation remain AF recurrence-free 3 month successful ablation continue meet inclusion/exclusion criterion screen enrollment trial . After fulfil inclusion/exclusion criterion , patient consent participate study remain AF recurrence-free randomize one two study arm : ( 1 ) OAT Withdrawal ( Test ) Group ( 2 ) OAT ( Control ) Group participate Evaluation Period ( 12 month ) .</detailed_description>
	<mesh_term>Atrial Fibrillation</mesh_term>
	<criteria>1 . Successful cardiac ablation AF 2 . Documented freedom AF recurrence ( symptomatic asymptomatic arrhythmic recurrence last longer 30 second ) 3 month successful cardiac ablation ( AF recurrence 3month blanking period exclude ) . 3 . Patient must commercially approve anticoagulation therapy least two ( 2 ) month prior randomization OAT Study . 4 . CHADS2 score ≥ 2 CHA2DS2VASc score ( ≥3 ) 5 . Left ventricular ejection fraction &gt; 25 % 6 . LA size &lt; 65 7 . High risk thromboembolic event ( i.e. , CHADS2 score ≥ 2 CHA2DS2VASc score ≥ 3 ) require OAT undergoing cardiac ablation 8 . Able willing comply pre followup test requirement 9 . Signed informed consent form 10 . Age 18 year old 1 . OAT require reason related AF ( i.e. , prosthetic valve , PV stenosis , previous pulmonary embolism , presence spontaneous echo contrast [ SEC ] standard echo perform 3months followup ) . 2 . Any cardiac surgery within past 60 day ( 2 month ) valvular cardiac surgical procedure time ( i.e. , ventriculotomy , atriotomy , valve repair replacement presence prosthetic valve ) 3 . Previous myocardial infarction ( MI ) percutaneous coronary intervention PCI within past 3 month 4 . Awaiting cardiac transplantation cardiac surgery within next 365 day ( 12 month ) 5 . Documented leave atrial thrombus 6 . Significant pulmonary disease , ( e.g. , restrictive pulmonary disease , constrictive COPD ) disease malfunction lungs respiratory system produce chronic symptom 7 . Significant medical problem opinion investigator would preclude enrollment study 8 . Women pregnant ( evidenced pregnancy test premenopausal ) 9 . Acute illness active systemic infection sepsis 10 . Unstable angina 11 . Contraindication anticoagulation ( i.e. , heparin , warfarin another commercially available anticoagulation medication ) 12 . History blood clot bleed abnormality 13 . Life expectancy le 360 day ( 12 month ) 14 . Uncontrolled Heart Failure NYHA Class III IV heart failure 15 . Enrollment clinical study evaluate another device drug , within past 6 month 16 . Unable unwilling comply protocol requirement</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Anticoagulation</keyword>
	<keyword>Oral</keyword>
	<keyword>Paroxysmal atrial fibrillation</keyword>
	<keyword>Patients post successful cardiac ablation</keyword>
	<keyword>Symptomatic high-burden paroxysmal AF</keyword>
	<keyword>3 month post procedure</keyword>
	<keyword>Remain free AF recurrence</keyword>
</DOC>